Compare SPDR Gold Trust (GLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Vertex Pharmaceuticals Incorporated — how do they compare? SPDR Gold Trust trades at $366, while Vertex Pharmaceuticals Incorporated trades at $479.31 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | VRTX | |
|---|---|---|
52-Week High | $495.90 | $529.59 |
52-Week Low | $300.96 | $366.54 |
Market Cap | — | $121.09B |
Sector | — | Health |
Enterprise Value | — | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, tracking physical gold prices, trades at $365.98, down 1.66% amid a bearish technical signal with moving averages indicating selling pressure. Recent U.S. economic data, including jobless claims and inflation figures, influence gold's short-term volatility, while central bank accumulation provides underlying support. The ETF lacks traditional financial ratios as it holds bullion, with performance tied directly to gold market dynamics and macroeconomic factors.
The outlook for GLD hinges on gold's response to Federal Reserve policy and geopolitical tensions, offering a hedge against inflation but facing headwinds from a stronger dollar and rising yields. Risks include interest rate sensitivity and market sentiment shifts, with investors monitoring key resistance near $375 for breakout potential.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
